Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > ME 23andMe > Detailed Quotes

ME 23andMe

Watchlist
2.870
-0.050-1.71%
Close 11/25 13:00 ET
2.900
+0.030+1.05%
Post Mkt Price 11/25 13:51 ET
High
2.930
Open
2.890
Turnover
3.21M
Low
2.830
Pre Close
2.920
Volume
1.11M
Market Cap
1.31B
P/E(TTM)
Loss
52wk High
9.240
Shares
455.48M
P/E(Static)
Loss
52wk Low
2.120
Float Cap
806.81M
Bid/Ask %
33.33%
Historical High
18.160
Shs Float
281.12M
Volume Ratio
0.82
Historical Low
2.120
Dividend TTM
--
Div Yield TTM
--
P/B
1.60
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.40%
Amplitude
3.43%
Avg Price
2.879
Lot Size
1
Float Cap
806.81M
Bid/Ask %
33.33%
Historical High
18.160
Shs Float
281.12M
Volume Ratio
0.82
Historical Low
2.120
Dividend TTM
--
P/B
1.60
Dividend LFY
--
Turnover Ratio
0.40%
Amplitude
3.43%
Avg Price
2.879
Lot Size
1
Price Forecast

No Data

News

Comment

Sign in to post a comment

No comment yet

Company Overview More
23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. It provides direct access to genetic information with multiple Food and Drug Administration authorizations for genetic health risk reports. The company operates under the Consumer and Research Services segment, and the Therapeutics segment. The firm’s research platform has generated publications on the genetic underpinnings of a range of diseases, conditions, and traits. The platform also powers the 23andMe therapeutics group, pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in South San Francisco, CA.
CEO: Ms. Anne Wojcicki
Market: NASDAQ
Listing Date: 06/17/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist